Advertisement

International Ophthalmology

, Volume 39, Issue 9, pp 1921–1930 | Cite as

The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when?

  • Mehmet Adnan Ozturk
  • Levent KorkmazEmail author
Original Paper

Abstract

Purpose

Retinopathy of prematurity (ROP), a proliferative vitreoretinopathy resulting from the vascular disorder of the retina, is the most frequent cause of blindness in childhood. In our time, ROP in advanced stage, a serious problem in premature infants, has no other treatment more effective and with fewer side effects than laser photocoagulation (LPC) treatment, which narrows visual field. The search for methods with fewer side effects than LPC has increased in recent times for the treatment of ROP. We aimed to investigate the effects in question of propranolol on ROP in various stages (stages 1, 2, and 3 ROP).

Methods

This study is designed as a randomized, placebo-controlled, single-centered, double-blind clinical trial with parallel groups. A total of 126 very preterm infants, followed up in our unit from April 2011 to January 2013, were randomly selected and included in our study. They were separated into the groups of 0, 1, and 2 depending on their stage of ROP. In addition, all the patients were divided into control group (CG) and propranolol treatment group (PTG). While the cases in the CG were administered physiological saline solution, the cases in the PTG were administered propranolol (2 mg/kg/day) in the neovascularization phase (second phase) of the ROP.

Results

Propranolol given to the group of stage 0–1 ROP was observed to have had no effect on the level of statistical significance between the CG and PTG in terms of increase in ROP stages (p > 0.05). However, propranolol was found to be more useful in patients with stage 2 ROP (p < 0.05).

Conclusion

When given in the neovascularization phase of the ROP, propranolol was found to be effective in the stage 2 (advanced stage) ROP patients but in stage 0–1 (early-stage) ROP patients, its efficacy was not sufficient.

Keywords

Very preterm infant Propranolol Retinopathy of prematurity Efficacy 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.

Informed consent

This study was approved by the Erciyes University ethical committee, Turkey. Written informed consent was obtained from the parents.

References

  1. 1.
    Fierson WM (2013) American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131:189–195CrossRefGoogle Scholar
  2. 2.
    Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P et al (2011) Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta adrenoreceptor blockade. Invest Ophthalmol Vis Sci 52:155–170CrossRefGoogle Scholar
  3. 3.
    Martini D, Monte MD, Ristori C, Cupisti E, Mei S, Fiorini P et al (2011) Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 119:1317–1329CrossRefGoogle Scholar
  4. 4.
    Korkmaz L, Baştuğ O, Ozdemir A, Korkut S, Karaca C, Akin MA et al (2016) The efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index. Curr Eye Res 3:1–10Google Scholar
  5. 5.
    Fleck BW (2013) Management of retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 98:454–456CrossRefGoogle Scholar
  6. 6.
    Rathi S, Jalali S, Patnaik S, Shahulhameed S, Musada GR, Balakrishnan D et al (2017) Abnormal complement activation and inflammation in the pathogenesis of retinopathy of prematurity. Front Immunol 22(8):1868CrossRefGoogle Scholar
  7. 7.
    Chan-Ling T, Gole GA, Quinn GE, Adamson SJ, Darlow BA (2018) Pathophysiology, screening and treatment of ROP: a multi-disciplinary perspective. Prog Retin Eye Res 62:77–119CrossRefGoogle Scholar
  8. 8.
    Ng EY, Connolly BP, McNamara JA, Regillo CD, Vander JF, Tasman W (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928–934CrossRefGoogle Scholar
  9. 9.
    Erbay A, Sarialioglu F, Malbora B, Yildirim SV, Varan B, Tarcan A et al (2010) Propranolol for infantile hemangiomas: a preliminary report on efficacy and safety in very low birth weight infants. Turk J Pediatr 52:450–456Google Scholar
  10. 10.
    Chen ML, Guo L, Smith LE, Dammann CE, Dammann O (2010) High or low oxygen saturation and severe retinopathy of prematurity. Pediatrics 125:1483–1492CrossRefGoogle Scholar
  11. 11.
    American Academy of Pediatrics (1984) An international classification of retinopathy of prematurity. Pediatrics 74:127–133Google Scholar
  12. 12.
    Fleck BW, McIntosh N (2009) Retinopathy of prematurity: recent developments. NeoReviews 10:e20–e30CrossRefGoogle Scholar
  13. 13.
    Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694CrossRefGoogle Scholar
  14. 14.
    Jobe AH, Bancalari E (2001) Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163:1723–1729CrossRefGoogle Scholar
  15. 15.
    Volpe JJ (2001) Neurology of the newborn, 4th edn. WB Saunders, PhiladelphiaGoogle Scholar
  16. 16.
    Bell MJ, Ternberg JL, Feigin RD (1978) Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 187:1–7CrossRefGoogle Scholar
  17. 17.
    Töllner U (1982) Early diagnosis of septicemia in the newborn. Clinical studies and sepsis score. Eur J Pediatr 138:331–337CrossRefGoogle Scholar
  18. 18.
    Kuriyama H, Waki M, Nakagawa M, Tsuda M (2001) Involvement of oxygen free radicals in experimental retinal ischemia and the selective vulnerability of retinal damage. Ophthalmic Res 33:196–202CrossRefGoogle Scholar
  19. 19.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S (2013) Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with age-related macular degeneration treated by bevacizumab. Retina 33:508–512CrossRefGoogle Scholar
  20. 20.
    Smith LE (2008) Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 49:5177–5182CrossRefGoogle Scholar
  21. 21.
    Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE (2009) Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 50:1329–1335CrossRefGoogle Scholar
  22. 22.
    Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G et al (2010) Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 18(10):83CrossRefGoogle Scholar
  23. 23.
    Blair BM, O’halloran HS, Puly TH, Stevens JL (2001) Decreased incidence of retinopathy of prematurity. J AAPOS 5:118–122CrossRefGoogle Scholar
  24. 24.
    Chen ML, Allred EN, Hecht JL, Onderdonk A, VanderVeen D, Wallace DK et al (2011) ELGAN Study. Placenta microbiology and histology and the risk for severe retinopathy of prematurity. Invest Ophthalmol Vis Sci 52:7052–7058CrossRefGoogle Scholar
  25. 25.
    Higgins RD, Mandelsohn AL, DeFeo MJ, Ucsel R, Hendricks-Munoz KD (1998) Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol 116:601–605CrossRefGoogle Scholar
  26. 26.
    Haigh JJ, Morelli PI, Gerhardt H, Haigh K, Tsien J, Damert A et al (2003) Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol 262:225–241CrossRefGoogle Scholar
  27. 27.
    Gibbs ME, Hutchinson DS, Summers RJ (2010) Noradrenaline release in the locus coeruleus modulates memory formation and consolidation; roles for a- and β-adrenergic receptors. Neuroscience 170:1209–1222CrossRefGoogle Scholar
  28. 28.
    Sullivan RM, Wilson DA, Leon M (1989) Norepinephrine and learning-induced plasticity in infant rat olfactory system. J Neurosci 9:3998–4006CrossRefGoogle Scholar
  29. 29.
    Dal Monte M, Casini G, la Marca G, Isacchi B, Filippi L, Bagnoli P (2013) Eye Drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Eye Res 111:27–35CrossRefGoogle Scholar
  30. 30.
    Filippi L, Cavallaro G, Berti E, Padrini L, Araimo G, Regiroli G et al (2017) Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. BMC Pediatr 17:165CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Division of Neonatology, Department of PediatricsErciyes University Medical FacultyKayseriTurkey

Personalised recommendations